We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Partner Therapeutics

News List

Partner Therapeutics’ inhaled sargramostim improves lung function in trial pharmaceutical-technology
March 02, 2021
Partner Therapeutics has reported positive top-line results from the investigator-led study of inhaled Leukine (sargramostim) in hospitalised Covid-19 patients.
Partner Therapeutics Wins $35M DoD Contract for Leukine in COVID-19 contractpharma
August 05, 2020
Funding will support two clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization filing.
Partner Therapeutics Announces Trial to Evaluate Leukine® for COVID-19 Respiratory Illness americanpharmaceuticalreview
March 30, 2020
Partner Therapeutics announced Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22).